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The minimum inhibitory concentration (MIC) of an antimicrobial drug for a bacterial pathogen is used as 
a measure of the bacterial susceptibility to the drug. However, relationships between the antimicrobial 
concentration, bacterial susceptibility, and the pharmacodynamic (PD) inhibitory effect on the bacterial 
population are more complex. The relationships can be captured by multi-parameter models such as the 
Emax model. In this study, time-kill experiments were conducted with a zoonotic pathogen Pasteurella 
multocida and the fluoroquinolone enrofloxacin. Pasteurella multocida isolates with enrofloxacin MIC 
of 0.01 μg/mL, 1.5 μg/mL, and 2.0 μg/mL were used. An additive inhibitory Emax model was fitted to 
the data on bacterial population growth inhibition at different enrofloxacin concentrations. The values 
of PD parameters such as maximal growth inhibition, concentration achieving a half of the maximal 
inhibition, and Hill coefficient that captures steepness of the relationships between the concentration 
and effect, varied between the isolate with low MIC and less susceptible isolates. While enrofloxacin 
PD against the isolate with low MIC exhibited the expected concentration-dependent characteristics, 
the PD against the less susceptible isolates demonstrated time-dependent characteristics. The results 
demonstrate that bacterial antimicrobial susceptibility may need to be described by a combination of 
parameters rather than a single parameter of the MIC.
Effective antimicrobial treatment regimens for bacterial infections are critical for achieving the therapeutic 
outcomes and minimizing development of bacterial antimicrobial resistance. Designing the regimens requires 
knowledge of the pharmacokinetics and pharmacodynamics of the antimicrobial drug in the host treated. The 
pharmacokinetic models project the drug concentrations over time in the bodily compartments where the infec-
tion is treated. The pharmacodynamics (PD) is how those concentrations affect the pathogen population. The 
antimicrobial’s minimum inhibitory concentration (MIC) for the pathogen is used as a standardized measure 
of the bacterial susceptibility to the drug (the minimum concentration that inhibits overnight visible growth of 
the bacterial isolate’s population culture when exposed to the drug at a standardized starting density). Then, the 
time the drug concentration in the infected organ remains above the MIC is considered for projecting the phar-
macodynamic effect against the pathogen population, and choose the dosing interval, for an antimicrobial which 
effect is expected to be time-dependent1,2. For an antimicrobial which effect against the pathogen population is 
expected to be concentration-dependent, the ratio of the peak drug concentration in the organ to the MIC and the 
area under the curve over the time when the concentration remains above MIC are considered1,2. Consequently, 
the dosing regimens for antimicrobial drugs that show a concentration-dependent PD for the pathogen tend to 
constitute higher doses administered less frequently, whereas those exhibiting a time-dependent relationship tend 
to constitute smaller doses administered more frequently.
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However, relationships between the antimicrobial concentration, bacterial susceptibility, and the PD-effect on 
the bacterial population are known to be more complex than what can be captured by the MIC parameter alone. 
Multi-parameter mathematical models have been developed to capture the relationships, such as the maximum 
effect (Emax) model based on the Hill function3,4. These models linked with those of the in vivo drug pharmacoki-
netics may better capture the microbiological efficacy of the dynamic antimicrobial exposure5,6. Still, once the Emax 
model’s form is chosen and its parameters’ values estimated for activity of the antimicrobial against the pathogen, 
the model is applied to different pathogen isolates under the assumption that the MIC is the only parameter that 
changes. In other words, within a given bacterial species, the values of the other PD parameters are assumed to 
be constant across the isolates with various MIC of the drug. Based on our review of experimental literature7, we 
hypothesized that this is not the case; the other PD parameters’ values may change between pathogen isolates for 
which the drug’s MIC differ. This can have significant clinical implications for design of antimicrobial treatment 
regimens, as then not only the MIC but also other PD parameters need to be considered when choosing the dose 
and dosing interval. Recent experimental evidence confirms this hypothesis for commensal Escherichia coli and 
a time-dependent antimicrobial tetracycline8. For example, larger values of the PD parameter Hill coefficient are 
observed for E. coli isolates with higher tetracycline MICs, compared to the isolates with lower MICs8. The value 
captures the steepness in relationships between an increase in the antimicrobial concentration and an increase in 
the PD-effect on growth of the exposed bacterial population.
The objective of this study was to test the hypothesis that for pathogenic bacteria’s isolates with different MIC 
of an antimicrobial drug, the values of the other PD parameters for the drug also differ. We experimented with 
Pasteurella multocida, which is both an important pathogen of animals, in particular cattle9,10, and a zoonotic 
bacteria with a wide host range and commonly present in infected animal wound bites in humans11–13. The anti-
microbial was the fluoroquinolone enrofloxacin, which is thought to exhibit the concentration-dependent activity 
against this pathogen14.
Results
PD model form. The data from the time-kill experiments are plotted in Fig. 1. Several formulations of the 
Emax model were compared for the fit to capture the relationships between the antimicrobial concentration and 
the rate of growth/decline of the exposed bacterial population. The best fit was observed for all three isolates for 
an additive inhibitory-effect Emax model with a sigmoid form for the relationships between an increase in the drug 
concentration and an increase in the inhibitory effect on the bacterial population growth. The Emax model is given 
in equation (1):
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Where:
 C - antimicrobial concentration.
 E(C) - bacterial population growth rate when exposed to concentration C.
 E0 - bacterial population growth rate in the absence of antimicrobial exposure.
 EC50 - concentration of the antimicrobial that achieves a 50% of the maximal inhibition of the bacterial popu-
lation growth rate.
 Emax - maximal inhibition of the bacterial population growth rate.
 H - Hill coefficient.
Parameter values of the PD model. The population growth rate in the absence of antimicrobial exposure, 
E0, was similar among the three P. multocida isolates, averaging at 0.3 per hour (Table 1). Hence, the growth rate 
appeared to be independent of the MIC. The values of the other PD parameters were statistically significantly differ-
ent for the isolate with enrofloxacin MIC of 0.01 μ g/mL compared to the isolates with the MIC of 1.5 and 2 μ g/mL 
(based on the non-overlapping 95% CI for the parameter estimates, Table 1). The highest maximal inhibition of 
the P. multocida population growth rate of 1.64 was observed for the isolate with enrofloxacin MIC of 0.01 μ g/mL. 
Furthermore, the EC50 for this isolate was 0.11 μ g/mL, which was 10 times higher than its MIC. The inhibition of 
the bacterial growth steeply increased with relatively small increases in drug concentration (Fig. 2a,b), and con-
tinued to increase at the concentrations of high MIC multiples (Fig. 3a,b). This was despite the Hill coefficient’s 
value close to 1, which otherwise would indicate a low steepness in the relationships between an increase in drug 
concentration and the bacterial growth inhibition. In contrast, the maximal inhibition of the bacterial population 
growth rate was 0.81 and 0.69 for the isolates with enrofloxacin MIC of 1.5 and 2 μ g/mL, respectively. The EC50 
values were close to the MIC, 2.13 and 1.60 μ g/mL, respectively. The inhibitory effect was less sensitive, compared 
to the more susceptible strain, to relatively small increases in drug concentration (Fig. 2c,d and e,f vs. a,b). This 
was despite relatively high values of the Hill coefficient, 3.05 and 4.37, respectively. Increases in drug concentra-
tion above 3 to 5 multiples of the MIC of the isolates had no further inhibitory effect on the bacterial population 
growth (Fig. 3c,d and e,f).
The pharmacodynamics of enrofloxacin is considered to be concentration-dependent, with the inhibitory 
effect on the bacterial population growth sensitive to relatively small increases in drug concentration, and an 
increase in the inhibitory effect continuing at drug concentrations above low MIC multiples. This indeed was 
observed for the isolate with enrofloxacin MIC of 0.01 μ g/mL, as indicated by the time-kill data (Fig. 1a), the 
high maximal growth inhibition of 1.64, and the EC50 value being several folds higher than the MIC (Table 1). 
The panels Fig. 2a,b visualize that the inhibitory effect on the isolate’s population growth rapidly increased with 
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an increase in the antimicrobial concentration. The panels Fig. 3a,b demonstrate that the increase continued 
at high MIC multiples. These clearly confirmed the concentration-dependent PD dynamics. In contrast, the 
time-kill data for P. multocida isolates with enrofloxacin MIC of 1.5 and 2 μ g/mL (Fig. 1b,c), the low maximal 
growth inhibition of 0.81 and 0.69, respectively, and the EC50 values close to the MIC values were suggestive of 
time-dependent PD. The inhibitory effect on the bacterial population growth was less sensitive to small increases 
in drug concentration (Fig. 2c,d and e,f) and only increased until the concentrations of low multiples of the MIC, 
after which the relationships exhibit a saturation with no further increase in the growth inhibition at higher drug 
concentrations (Fig. 3c,d and e,f).
Also, interestingly, the simulations demonstrated that the possible inhibitory PD effect on bacterial growth and 
the resulting bacterial density trajectories were more variable for the isolate with enrofloxacin MIC of 0.01 μ g/mL, 
compared to the isolates with higher MIC values (Fig. 2a,b vs. c,d and e,f; Fig. 3a,b vs. c,d and e,f). This was 
because for the former the Hill coefficient estimate was close to 1 and the maximal inhibition of the growth , Emax, 
was a relatively high value (Table 1). A random variability in individual bacterial populations could result in a 
Figure 1. Data from the time-kill experiments for three Pasteurella multocida isolates: (a) isolate with 
enrofloxacin MIC = 0.01 μ g/mL; (b) isolate with enrofloxacin MIC = 1.5 μ g/mL; and (c) isolate with 
enrofloxacin MIC = 2.0 μ g/mL. Each point is the geometric mean of the bacterial densities in two independent 
experiments. CFU – colony forming units.
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Hill coefficient value above or below 1, and relatively larger deviations in the maximal inhibition. The trajectories 
of the bacterial populations of the isolates with higher MIC under the antimicrobial exposure appeared more 
predictable (Figs 2c,e; Fig. 3c,e), likely because of the relatively high Hill coefficient values.
Discussion
In this study, the maximal inhibition of P. multocida population growth (Emax) was statistically significantly 
higher for the isolate with the lowest enrofloxacin MIC compared to the isolates with higher MIC values. Also 
for the former, the concentration at which 50% of Emax was achieved, EC50, was significantly greater relative to 
the MIC (Table 1). The inhibition of the population growth of the more susceptible isolate was more sensitive 
to smaller changes in the antimicrobial concentration, and the effect continued to respond to an increase in 
the concentrations above several multiples of the MIC (Figs 2a,b and 3a,b). This corresponded to the expected 
concentration-dependent PD dynamics of enrofloxacin, a fluoroquinolone antimicrobial. In contrast, the inhibi-
tion of the population growth for the isolates with higher MIC was less sensitive to increases in the antimicrobial 
concentration, and the effect plateaued at the concentrations of low MIC multiples (Fig. 2c,d and e,f; Fig. 3c,d 
and e,f). Thus, the PD dynamics were more in line with time-dependent characteristics. These observations may 
seem counterintuitive given the estimated Hill coefficient value of 1 for the isolate with the lowest MIC, compared 
the large Hill coefficient values, 3 to 4, for less susceptible isolates. However, the steepness of the relationships 
between an increase in the antimicrobial concentration and the inhibitory effect on the pathogen population – the 
slope of the concentration-effect curve - is dependent on the combination of the PD parameters. In particular, 
the high Hill coefficient values for the isolates with higher enrofloxacin MIC did not offset the impacts of the low 
EC50 and Emax values (Table 1).
The direction of change in the PD-parameter Hill coefficient among bacterial isolates with different MIC 
(determined under the standard conditions) of the fluoroquinolone enrofloxacin for zoonotic pathogen P. mul-
tocida in this study was similar to that reported for commensal E. coli for tetracycline8. The magnitude of the 
change was also remarkably similar between the two bacteria-antimicrobial systems. A three to four fold increase 
in the Hill coefficient value was observed for P. multocida isolates with enrofloxacin MIC of 1.5 or 2 μ g/mL, 
compared to the isolate with the MIC of 0.01 μ g/mL (Table 1). Based on the data presented in Ahmad et al.8, the 
average value of Hill-coefficient for E. coli isolates with tetracycline MIC above 2 μ g/mL was four times that for 
the isolates with tetracycline MIC below 0.5 μ g/mL. This consistency is notable, given that enrofloxacin exhib-
its the concentration-dependent PD dynamics against highly susceptible bacterial isolates as described by the 
MIC14 (including in this study for the isolate with the MIC of 0.01 μ g/mL). In contrast, tetracycline exhibits the 
time-dependent PD dynamics irrespectively of the bacterial susceptibility as described by the MIC8. Moreover, 
the fluoroquinolone enrofloxacin is bactericidal but tetracycline is bacteriostatic at the concentrations achievable 
in the body15.
On the other hand, while the value of the PD-parameter EC50 increased in line with the increase in MIC of the 
isolates in both these bacteria-antimicrobial systems, the relationships between the EC50 and MIC for a given iso-
late differed. For activity of tetracycline against E. coli, the EC50 was below the MIC for majority of the isolates with 
either a relatively low or high MIC8, as could be expected for an antimicrobial with the primarily time-dependent 
PD. For activity of enrofloxacin against P. multocida, the EC50 was several folds higher than the MIC for the 
isolate with the lowest MIC studied, 0.01 μ g/mL, as could be expected for the concentration-dependent PD. For 
the isolates with enrofloxacin MIC of 1.5 or 2 μ g/mL, the EC50 was close to the MIC (Table 1), highlighting the 
change towards more time-dependent characteristics. The maximal inhibition of the bacterial population growth 
achieved at high antimicrobial concentrations, Emax, was approximately twice less for the P. multocida isolates with 
enrofloxacin MIC of 1.5 or 2 μ g/mL, compared to the isolate with the MIC of 0.01 μ g/mL in this study (Table 1). 
This parameter was not reported by Ahmad et al.8, and therefore could not be compared.
Based on the experimental results of this study and those in Ahmad et al.8, and also earlier theoretical 
considerations16, a question could be raised about how to define the susceptibility of a bacterial isolate to an 
Isolate source MIC(μg/mL) Parameter Estimate CV (%)
2.5% CI of 
the estimate
97.5% CI of 
the estimate
Bovine lung 0.01
Emax 1.64 8.47 1.34 1.93
EC50, μ g/mL 0.11 11.49 0.08 0.13
E0, log(CFU/mL) x hour−1 0.32 8.86 0.26 0.38
H 0.97 11.97 0.73 1.22
Bovine nasal swab 1.50
Emax 0.81 9.07 0.65 0.96
EC50, μ g/mL 2.13 13.13 1.53 2.72
E0, log(CFU/mL) x hour−1 0.31 10.40 0.24 0.38
H 3.05 14.22 2.13 3.97
Bovine nasal swab 2.00
Emax 0.69 4.37 0.63 0.75
EC50, μ g/mL 1.60 3.38 1.49 1.72
E0, log(CFU/mL) x hour−1 0.29 3.11 0.27 0.30
H 4.37 17.28 2.77 5.97
Table 1.  Estimates of pharmacodynamic parameters of enrofloxacin against Pasteurella multocida isolates 
with different MIC.
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antimicrobial. The results jointly demonstrate that susceptibility cannot be simply described by the antimicrobi-
al’s MIC. The effects of the dynamic antimicrobial exposure in vivo on the pathogen population also will depend 
on the responsiveness of the isolate to a change in the drug concentration. The steepness (which depends on the 
combination of the PD parameters) of the relationships between an increase in the drug concentration and the 
inhibitory effect on the bacterial population is a feature of the bacterial susceptibility. Thus, the entire combina-
tion of PD parameters that reflect the isolate’s susceptibility, not only the MIC, can be taken into account when 
designing the treatment regimens. This can have significant clinical implications, pertaining to the antimicrobial’s 
dose and dosing interval needed to address pathogen’s isolates with different susceptibilities. Simple “rules of 
thumb” may not apply and the complete PD profile for pathogen isolates of different susceptibilities should be 
considered along with the antimicrobial drug’s pharmacokinetics and toxicological considerations in the host 
Figure 2. The simulated distributions of the rate of bacterial population growth/decline for three Pasteurella 
multocida isolates: (a) isolate with enrofloxacin MIC = 0.01 μ g/mL; (c) isolate with enrofloxacin MIC = 1.5 μ g/mL; 
and (e) isolate with enrofloxacin MIC = 2.0 μ g/mL. The resulting bacterial density after 1-hour exposure to different 
enrofloxacin concentrations, with the starting density 5 × 105 CFU/mL, for three Pasteurella multocida isolates:  
(b) isolate with enrofloxacin MIC = 0.01 μ g/mL; (d) isolate with enrofloxacin MIC = 1.5 μ g/mL; and (f) isolate with 
enrofloxacin MIC = 2.0 μ g/mL. In each panel or box-plot, the outputs of 1,000 simulations for each enrofloxacin 
concentration of the best-fit pharmacodynamic model for the isolate are summarized. CFU – colony forming units.
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to design effective treatment regimens. The data also suggest that should antimicrobial resistance occur in the 
pathogen under treatment, a different dosage regimen may be required; this is not currently being considered in 
clinical settings.
Methods
Bacterial isolates and antimicrobial agent. Three isolates of P. multocida from respiratory organs of 
cattle were obtained from the Kansas State Veterinary Diagnostic Laboratory. Enrofloxacin (Sigma-Aldrich, St. 
Louis, MO, USA) stock solutions (1 mg/mL) were prepared in methanol.
Figure 3. The simulated distributions of the rate of bacterial population growth/decline for three Pasteurella 
multocida isolates: (a) isolate with enrofloxacin MIC = 0.01 μ g/mL; (c) isolate with enrofloxacin MIC = 1.5 μ g/mL; 
and (e) isolate with enrofloxacin MIC = 2.0 μ g/mL. The resulting bacterial density after 1-hour exposure to different 
enrofloxacin concentrations standardized as multiples of the isolate’s MIC, with the starting density 5 × 105 CFU/mL, 
for three Pasteurella multocida isolates: (b) isolate with enrofloxacin MIC = 0.01 μ g/mL; (d) isolate with enrofloxacin 
MIC = 1.5 μ g/mL; and (f) isolate with enrofloxacin MIC = 2.0 μ g/mL. In each panel or box-plot, the outputs of 
1,000 simulations for each enrofloxacin concentration of the best-fit pharmacodynamic model for the isolate are 
summarized. CFU – colony forming units.
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MIC estimation. Susceptibility of each isolate to enrofloxacin was evaluated by measuring the MIC by the broth 
microdilution method performed in accordance with the Clinical and Laboratory Standards Institute’s recommen-
dations17, and by the E-test® performed in accordance with the manufacturer’s recommendations (bioMérieux, 
Marcy-l'Étoile, France). An isolate with enrofloxacin MIC = 0.01 μ g/mL, another with MIC = 1.5 μ g/mL, 
and a third isolate with MIC = 2 μ g/mL were included in the time-kill experiments.
Time-kill experiments. The time-kill protocol was an adaptation of that previously described18. Briefly, 
bacteria were grown aerobically in 20 mL of brain heart infusion broth (BHI, RemelTM, Lenexa, KS, USA) at 
37 °C with shaking (200 rpm) overnight. The overnight cultures were diluted 1:200 into fresh BHI and incubated 
at 37 °C for 30 minutes, and then diluted 1:20 into flasks containing fresh BHI with different concentrations of 
enrofloxacin for the time-kill experiments. The starting bacterial densities in the experiments were 105 to 106 
colony forming units (CFU) per mL; the densities were estimated by serially diluting the culture in 0.9% sterile 
saline solution and direct plating the solute on tryptic soy agar with 5% sheep blood (RemelTM, Lenexa, KS, USA). 
Seven enrofloxacin concentrations were used for each isolate, normalized to 0 (control), 0.5, 0.75, 1, 2, 3, 5, and 
10 multiples of the isolate’s MIC. The cultures with the antimicrobial were incubated aerobically with shaking 
(200 rpm) at 37 °C and sampled at 0, 1, 2, 3, 4, 5, 6, 7, 8, 12, and 24 hour of the incubation. The bacterial densities 
at each time point were estimated, similarly to as described above.
Fitting PD model: model form. For each bacterial isolate, antimicrobial concentration, and time-kill 
experiment, the bacterial population density was plotted vs. time on a semi-logarithmic scale (the density 
log10-transformed). The population growth/decline rate was determined as the slope of the population density 
line during the initial linear phase. These rates together with the associated drug concentrations constituted the 
dataset. The relationships between the antimicrobial concentration and the bacterial population growth/decline 
rate were investigated by fitting to the dataset different forms of the Emax model. We investigated fit of a model 
formulated with an additive or fractional inhibitory PD-effect on the growth, and with or without a sigmoid form 
for the relationships. The models were fitted to the dataset as nonlinear mixed-effect regression models using the 
maximum likelihood method in the Phoenix® NLME software (Certara USA, Inc., Princeton, NJ, USA). The 
fixed effect in the models was the antimicrobial concentration; the experiment was added as a random effect. 
Selection of the model form was based on the minimization of the Akaike Information Criterion (AIC); visual 
inspection of the goodness of fit of the predicted to the observed rate of the bacterial growth/decline at different 
drug concentrations; and visual inspection of the diagnostic plots for the residuals for outliers or trends which 
would suggest a poor model fit. Precision of the parameter estimates was also considered, and considered accept-
able if the coefficient of variation was ≤ 25%.
Fitting PD model: model’s parameter values. Once the best-fit PD model form was determined, the 
parameters’ values were compared among the three isolates. The values of a parameter were considered statisti-
cally significantly different between each two isolates if there was no overlap of the 95% Confidence Intervals (CI) 
for the parameter estimates.
Simulating distributions of the time-kill curves. To visualize the antimicrobial PD against the bacte-
rial isolates with different MIC values for the antimicrobial, we simulated the possible distributions of the rate 
of bacterial population growth/decline and the resulting bacterial density after a 1 hour exposure to different 
enrofloxacin concentrations. For each isolate, 1,000 Monte Carlo simulations of the best-fit PD model were per-
formed with the parameters’ values obtained by Latin hypercube sampling19, from the parameters’ distributions 
assumed to each follow a Uniform (as in refs 20 and 21). The limits of the sampled distribution corresponded to 
the 95% CI of the parameter estimate, for each Emax, EC50, or Hill coefficient, for that isolate (Table 1). The same 
distribution of the underlying bacterial population growth rate, E0, was sampled for all three isolates, a Uniform 
(0.24; 0.38), corresponding to the variability observed in the experiments (Table 1). Examination of the Cholesky 
decomposition of the matrix of variances and covariances from the non-linear mixed-effect regression model 
fit to the experimental data did not reveal any covariances among the parameters; therefore each parameter was 
sampled independently for the simulations. The simulations were implemented using the 4th order Runge-Kutta 
algorithm in Vensim® Professional software (Ventana Systems Inc., Harvard, MA, USA). The outputs were plot-
ted in SigmaPlot™ (Systat Software Inc., San Jose, CA, USA).
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